MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Vernalis to resubmit NDA to US FDA for drug CCP-07

StockMarketWire.com

Vernalis said a complete response letter (CRL) from the US FDA did not raise any concerns with the formulation or pharmacokinetic profile of CCP-07, but identified outstanding items that needed to be addressed prior to the resubmission and approval of a new drug application (NDA).

A CRL was issued by the FDA when it had completed its review of an NDA and questions remained that preclude its approval at this time.

"We remain committed to the approval of CCP-07 and will work closely with the FDA to resubmit the NDA as quickly as possible" said Vernalis' CEO, Ian Garland.

Separately, Vernalis said it had received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising its fragment and structure-based drug discovery platform.





Story provided by StockMarketWire.com